Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Biocon Limited
  6. Summary
    BIOCON   INE376G01013

BIOCON LIMITED

(BIOCON)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nse India Stock Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
389.5(c) 379.55(c) 381.7(c) 382.55(c) 386.35(c) Last
2 134 036 4 496 288 1 969 181 7 709 849 2 792 729 Volume
-2.17% -2.55% +0.57% +0.22% +0.99% Change
More quotes
Estimated financial data (e)
Sales 2022 84 063 M 1 131 M 1 131 M
Net income 2022 7 931 M 107 M 107 M
Net Debt 2022 30 456 M 410 M 410 M
P/E ratio 2022 57,1x
Yield 2022 0,26%
Sales 2023 103 B 1 383 M 1 383 M
Net income 2023 13 256 M 178 M 178 M
Net Debt 2023 30 262 M 407 M 407 M
P/E ratio 2023 34,1x
Yield 2023 0,38%
Capitalization 460 B 6 181 M 6 182 M
EV / Sales 2022 5,83x
EV / Sales 2023 4,76x
Nbr of Employees 13 500
Free-Float 34,6%
More Financials
Company
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and... 
More about the company
Ratings of Biocon Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about BIOCON LIMITED
07/29Biocon Biologics and Viatris Inc. Receive Approval for First Interchangeable ..
CI
07/26BIOCON : Arm Gets License from US Company for COVID-19 Monoclonal Antibody
MT
07/23John McCallum Marshall Shaw to Step Down as Vice-Chairperson (Non-Executive, ..
CI
07/23BIOCON : Consolidated Profit Slides 44% in Fiscal Q1
MT
07/22Biocon Limited Reports Earnings Results for the First Quarter Ended June 30, ..
CI
05/07BIOCON : Insulin Glargine Biosimilar Insight, 2020 | Report by DelveInsight
AQ
04/29BIOCON : Names New CFO
MT
04/28BIOCON : Net Profit Surges 105% in March Quarter
MT
04/28Biocon Limited Announces Executive Changes
CI
04/28Biocon Limited Announces CFO Change
CI
04/28Biocon Limited Reports Earnings Results for the Fourth Quarter Ended March 31..
CI
04/28BIOCON : Syngene targets delivering 500,000 vials of remdesivir in India as COVI..
RE
04/26BIOCON : Unit Gets European Commission's Approval for Biosimilar of Cancer Drug
MT
04/22BIOCON : India posts world record COVID cases with oxygen running out
RE
04/11India bans Remdesivir exports as coronavirus rages on; rallies continue
RE
More news
News in other languages on BIOCON LIMITED
02/23Farmacéuticas indias se vuelven locales para terminar con dependencia de Chin..
2020Novartis obtient une décision favorable d'un tribunal US sur Gilenya
2020Novartis begrüsst Entscheidung von US-Gericht zu Gilenya (fingolimod)
2020VOLUNTIS : accord de collaboration avec Biocon Biologics
2020India aprueba un fármaco de Biocon contra el coronavirus para su uso en pacie..
More news
Chart BIOCON LIMITED
Duration : Period :
Biocon Limited Technical Analysis Chart | BIOCON | INE376G01013 | MarketScreener
Technical analysis trends BIOCON LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Last Close Price 386,35 INR
Average target price 394,79 INR
Spread / Average Target 2,18%
EPS Revisions
Managers and Directors
Siddharth Mittal Chief Executive Officer, Director & MD
Indranil Sen Chief Financial Officer
Kiran Mazumdar-Shaw Executive Chairman
Manoj Kumar Pananchukunnath Head-Regulatory Sciences, Research & Development
Sandeep Nilkanth Athalye Head-Clinical Development & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
BIOCON LIMITED-16.99%6 181
GILEAD SCIENCES, INC.19.86%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%68 112
REGENERON PHARMACEUTICALS20.70%59 505
VERTEX PHARMACEUTICALS-14.71%52 232